Stock Price & Analysis

Buy DNLI stock as analysts maintain a Strong Buy rating with a $38.79 price target, indicating significant upside potential. Despite the recent trial setback, the company's pipeline and strategic progress support long-term growth.

Price Prediction for DNLI Stock in 2025

Based on current trends and analyst expectations, DNLI stock is predicted to reach $20.00 by 2025. This forecast is supported by the company's promising drug pipeline and strong analyst consensus, despite recent setbacks in clinical trials. The stock's upside potential is further bolstered by its current undervaluation relative to its growth prospects.

The S1 support level for DNLI Stock is $14.35 ,The R1 resistant level for DNLI Stock is $16.13.

As of the end of day on 2025-03-24, the price of DNLI Stock was $14.63.

The target price for DNLI Stock according to analyst rating is 38.57, with the highest price target at 80.00 and the lowest at 24.00. Analysts have a Strong Buy rating on DNLI Stock overall.

The market cap of DNLI is $2.1B.

DNLI appears overvalued given its current financials and recent developments. The stock trades at $14.51 with a $2.1B market cap, yet it has negative revenues and net income, with a net margin of -35.09% to -37.40%. Despite a strong analyst consensus with a $38.79 target, the failed Phase 2/3 trial for DNL343 and lack of significant revenue raise concerns about its valuation. The company's reliance on future pipeline success and high R&D expenses add risk. While its pipeline potential is promising, current fundamentals suggest overvaluation.

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Denali Therapeutics (DNLI) is expected to reach a stock price of $50 to $70 by 2030, driven by its promising drug pipeline and potential FDA approvals for key treatments like Tividenofusp alfa. The company's ETV platform and strategic expansions position it for significant growth in neurodegenerative diseases. However, this prediction hinges on successful clinical trials and regulatory outcomes.

DNLI has a total of 445 employees.